Table 3.
Association between plasma fluorescent oxidation products and risk of hip fracture
| Tertile 1 | Tertile 2 | Tertile 3 | P for trend | |
|---|---|---|---|---|
| FlOP_360 | ||||
| Range (FI/ml) | < 192 | ≥ 192; < 255 | ≥ 255 | --- |
| Median (FI/ml) | 163 | 215 | 338 | --- |
| Incidence of hip fracture (n, %) | 15 (4.5%) | 17 (5.1%) | 12 (3.6%) | --- |
| Adjusted for age | 1 (ref) | 1.13 (0.56, 2.26) | 0.85 (0.40, 1.81) | 0.638 |
| Adjusted for age and hypertension | 1 (ref) | 1.16 (0.58, 2.32) | 0.79 (0.37, 1.69) | 0.540 |
| Adjusted for multiple risk factors* | 1 (ref) | 1.03 (0.50, 2.14) | 0.70 (0.32, 1.54) | 0.386 |
|
| ||||
| FlOP_320 | ||||
| Range (FI/ml) | < 335 | ≥ 335; < 546 | ≥ 546 | --- |
| Median (FI/ml) | 270 | 404 | 1337 | --- |
| Incidence of hip fracture (n, %) | 9 (2.7%) | 15 (4.5%) | 20 (6.0%) | --- |
| Adjusted for age | 1 (ref) | 1.81 (0.79, 4.14) | 2.51 (1.14, 5.52) | 0.012 |
| Adjusted for age and hypertension | 1 (ref) | 1.78 (0.78, 4.06) | 2.35 (1.07, 5.18) | 0.015 |
| Adjusted for multiple risk factors* | 1 (ref) | 2.11 (0.88, 5.10) | 2.67 (1.14, 6.27) | 0.021 |
|
| ||||
| FlOP_400 | ||||
| Range (FI/ml) | < 52.9 | ≥ 52.9; < 72.9 | ≥ 72.9 | --- |
| Median (FI/ml) | 45.6 | 61.0 | 93.4 | --- |
| Incidence of hip fracture (n, %) | 15 (4.5%) | 17 (5.1%) | 12 (3.6%) | --- |
| Adjusted for age | 1 (ref) | 1.12 (0.56, 2.25) | 0.89 (0.42, 1.91) | 0.973 |
| Adjusted for age and hypertension | 1 (ref) | 1.15 (0.57, 2.30) | 0.84 (0.39, 1.81) | 0.875 |
| Adjusted for multiple risk factors* | 1 (ref) | 1.21 (0.58, 2.52) | 0.88 (0.40, 1.96) | 0.900 |
Values are hazard ratios (95% confidence interval), unless otherwise specified. FlOP = Fluorescent oxidation products, FI = Fluorescent intensity units.
Risk factors included age (continuous), history of hypertension (yes/no), body mass index (< 25, ≥ 25 and < 30, ≥30 and <35, and ≥ 35 kg/m2), fasting status (< 8 and ≥ 8 hours), time and month of blood draw, alcohol intake (In quartiles: 0, > 0 and <1, ≥ 1 and < 6.7, and ≥ 6.7 g/day), physical activity (In quartiles: < 5.2, ≥ 5.2 and < 12.7, ≥ 12.7 and < 25.9, and ≥ 25.9 MET-hours/week), total calcium intake (In quartiles: < 667, ≥ 667 and < 969, ≥ 969 and < 1347, and ≥ 1347 mg/day), total vitamin D intake (In quartiles: < 187, ≥ 187 and < 303, ≥ 303 and < 536, and ≥ 536 IU/day), history of osteoporosis (yes/no) and postmenopausal hormone therapy (yes/no).